Boston Scientific Corporation

Boston Scientific Corporation. It is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company's products are instrumental in treating conditions within cardiology, peripheral interventions, endoscopy, urology, pelvic health, and neuromodulation. Headquartered in Marlborough, Massachusetts, it operates in over 100 countries and is a constituent of the S&P 500 and FTSE 100 Index.

History

The company was founded in 1979 in Marlborough, Massachusetts by entrepreneurs John Abele and Pete Nicholas. Its early growth was fueled by the 1988 acquisition of Medi-Tech, which provided foundational technology in steerable catheters. A pivotal moment came in 1995 with the $4.2 billion purchase of SCIMED Life Systems, significantly expanding its portfolio in interventional cardiology. The company became publicly traded on the New York Stock Exchange in 1992. Major strategic acquisitions have continued to shape its portfolio, including the purchases of Guidant Corporation's vascular intervention and endovascular businesses in 2006, C.R. Bard's electrophysiology division in 2012, and BTG plc in 2019 to strengthen its interventional medicine capabilities. In 2023, it completed the acquisition of Axonics, Inc., a leader in neuromodulation for pelvic health disorders.

Products

The company's extensive portfolio is organized into two primary segments: MedSurg and Cardiovascular. The MedSurg segment includes devices for endoscopic procedures, urological and pelvic health conditions, and neuromodulation therapies for chronic pain and movement disorders. Key products here include the LithoVue single-use digital ureteroscope and the SpaceOAR hydrogel for prostate cancer radiotherapy. The Cardiovascular segment encompasses technologies for coronary and peripheral artery disease, as well as structural heart conditions. This includes the SYNERGY bioabsorbable polymer drug-eluting stent, the WATCHMAN FLX left atrial appendage closure device, and the Ranger drug-coated balloon. The portfolio also features critical devices for treating bradycardia and tachycardia through its electrophysiology offerings.

Operations

The company maintains a significant global manufacturing and research footprint, with major facilities across the United States, Ireland, Costa Rica, and Malaysia. Its principal research and development centers are located in Marlborough, Massachusetts, Maple Grove, Minnesota, and Cork, Ireland. Operations are divided into three regional business units: U.S.; Europe, Middle East and Africa (EMEA); and Asia-Pacific (APAC), which includes a substantial presence in Japan and China. The company invests heavily in research and development, collaborating with leading clinical institutions like the Cleveland Clinic and Mayo Clinic to advance minimally invasive therapies. Its supply chain and logistics network is designed to support customers in over 100 countries.

Corporate affairs

Michael F. Mahoney has served as the company's Chairman and Chief Executive Officer since 2012. The corporate headquarters are located in Marlborough, Massachusetts, with its common stock listed on the New York Stock Exchange under the symbol "BSX". The company emphasizes a culture of innovation and global citizenship, with initiatives focused on expanding access to healthcare in underserved communities through partnerships with organizations like World Heart Federation. It is recognized annually in lists such as the Dow Jones Sustainability Index for its environmental, social, and governance performance. The Boston Scientific Foundation supports community health and STEM education programs.

Legal and regulatory issues

Like many major medical device companies, it has faced significant legal and regulatory challenges. This included a long-running series of product liability lawsuits and a Department of Justice investigation related to certain pelvic mesh products, acquired from American Medical Systems, which were largely resolved through a major settlement in 2019. The company has also navigated complex regulatory pathways with the U.S. Food and Drug Administration (FDA) for product approvals, including receiving PMA (Premarket Approval) for devices like the WATCHMAN. It operates under a Corporate Integrity Agreement with the HHS-OIG and maintains a comprehensive compliance program adhering to regulations like the Foreign Corrupt Practices Act.